|   |   |                                                                                                                                             |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| þ |   | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2012.  |

|   |   |                                                                                                                                                   |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| o      |   | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from __________ to __________. |

|                                     |   |                |
|------------------------------------------|--------|---------------------|
| DELAWARE                                 |   | 74-2747608          |
| (State or other jurisdiction of          |   | (I.R.S. Employer    |
| incorporation or organization)           |   | Identification No.) |
|                                     |   |                |
| 12212 TECHNOLOGY BLVD., AUSTIN, TEXAS    |   | 78727               |
| (Address of principal executive offices) |   | (Zip Code)          |

| Large accelerated filer þ                                      |   | Accelerated filer o         |
|---------------------------------------------------------------------|--------|-----------------------------|
| Non-accelerated filer o (Do not check if smaller reporting company) |   | Smaller reporting company o |
|                                                                |   |                        |

----

TABLE OF CONTENTS

|                                                                                                                |   |   |
|---------------------------------------------------------------------------------------------------------------------|--------|--------|
|                                                                                                                |   | Page   |
|                                                                                                                |   |   |
| PART I. FINANCIAL INFORMATION                                                                                       |   |   |
|                                                                                                                |   |   |
| Item 1. Financial Statements                                                                                        |   |   |
|                                                                                                                |   |   |
| Condensed Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011                                     |   | 1      |
|                                                                                                                |   |   |
| Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2012 and 2011 |   | 2      |
|                                                                                                                |   |   |
| Condensed Consolidated Statements of Cash Flows for the three and six months ended June 30, 2012 and 2011           |   | 3      |
|                                                                                                                |   |   |
| Notes to Condensed Consolidated Financial Statements                                                                |   | 4      |
|                                                                                                                |   |   |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations                 |   | 13     |
|                                                                                                                |   |   |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk                                                  |   | 27     |
|                                                                                                                |   |   |
| Item 4. Controls and Procedures                                                                                     |   | 28     |
|                                                                                                                |   |   |
| PART II. OTHER INFORMATION                                                                                          |   |   |
|                                                                                                                |   |   |
| Item 1A. Risk Factors                                                                                               |   | 28     |
|                                                                                                                |   |   |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds                                                 |   | 28     |
|                                                                                                                |   |   |
| Item 6. Exhibits                                                                                                    |   | 29     |
|                                                                                                                |   |   |
| SIGNATURES AND EXHIBITS                                                                                             |   | 30     |
|                                                                                                                |   |   |
| Exhibit 10.1                                                                                                        |   |   |
| Exhibit 10.2                                                                                                        |   |   |
| Exhibit 31.1                                                                                                        |   |   |
| Exhibit 31.2                                                                                                        |   |   |
| Exhibit 32.1                                                                                                        |   |   |
| Exhibit 32.2                                                                                                        |   |   |
| EX-101 INSTANCE DOCUMENT                                                                                            |   |   |
| EX-101 SCHEMA DOCUMENT                                                                                              |   |   |
| EX-101 CALCULATION LINKBASE DOCUMENT                                                                                |   |   |
| EX-101 DEFINITION LINKBASE DOCUMENT                                                                                 |   |   |
| EX-101 LABELS LINKBASE DOCUMENT                                                                                     |   |   |
| EX-101 PRESENTATION LINKBASE DOCUMENT                                                                               |   |   |

----

Table of Contents

PART

ITEM 1

| LUMINEX CORPORATION                                                                                                                                              |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| CONDENSED CONSOLIDATED BALANCE SHEETS                                                                                                                            |   |
| (in thousands)                                                                                                                                                   |   |
|                                                                                                                                                             |   |   |   |   |   |   |
|                                                                                                                                                             |   | June 30, 2012 |   |   | December 31, 2011 |   |
|                                                                                                                                                             |   | (unaudited) |   |   |   |   |
| ASSETS                                                                                                                                                           |   |   |   |   |   |   |
| Current assets:                                                                                                                                                  |   |   |   |   |   |   |
| Cash and cash equivalents                                                                                                                                        |   | $ | 75,898 |   |   | $ | 58,282 |   |
| Restricted cash                                                                                                                                                  |   |   | - |   |   |   | 1,006 |   |
| Short-term investments                                                                                                                                           |   |   | 23,150 |   |   |   | 42,574 |   |
| Accounts receivable, net                                                                                                                                         |   |   | 26,176 |   |   |   | 23,016 |   |
| Inventories, net                                                                                                                                                 |   |   | 26,304 |   |   |   | 24,579 |   |
| Deferred income taxes                                                                                                                                            |   |   | 4,416 |   |   |   | 5,991 |   |
| Prepaids and other                                                                                                                                               |   |   | 4,924 |   |   |   | 3,529 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Total current assets                                                                                                                                             |   |   | 160,868 |   |   |   | 158,977 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Property and equipment, net                                                                                                                                      |   |   | 26,243 |   |   |   | 25,192 |   |
| Intangible assets, net                                                                                                                                           |   |   | 27,256 |   |   |   | 29,437 |   |
| Deferred income taxes                                                                                                                                            |   |   | 13,461 |   |   |   | 12,817 |   |
| Long-term investments                                                                                                                                            |   |   | 5,997 |   |   |   | 6,151 |   |
| Goodwill                                                                                                                                                         |   |   | 42,758 |   |   |   | 42,763 |   |
| Other                                                                                                                                                            |   |   | 6,899 |   |   |   | 7,310 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Total assets                                                                                                                                                     |   | $ | 283,482 |   |   | $ | 282,647 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                                                             |   |   |   |   |   |   |   |   |
| Current liabilities:                                                                                                                                             |   |   |   |   |   |   |   |   |
| Accounts payable                                                                                                                                                 |   | $ | 5,937 |   |   | $ | 5,941 |   |
| Accrued liabilities                                                                                                                                              |   |   | 9,714 |   |   |   | 11,047 |   |
| Deferred revenue                                                                                                                                                 |   |   | 4,230 |   |   |   | 4,057 |   |
| Current portion of long-term debt                                                                                                                                |   |   | 490 |   |   |   | 999 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Total current liabilities                                                                                                                                        |   |   | 20,371 |   |   |   | 22,044 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Long-term debt                                                                                                                                                   |   |   | 2,191 |   |   |   | 2,573 |   |
| Deferred revenue                                                                                                                                                 |   |   | 3,259 |   |   |   | 3,344 |   |
| Other                                                                                                                                                            |   |   | 2,584 |   |   |   | 3,831 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Total liabilities                                                                                                                                                |   |   | 28,405 |   |   |   | 31,792 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Stockholders' equity:                                                                                                                                            |   |   |   |   |   |   |   |   |
| Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 41,110,756 shares at June 30, 2012; 40,968,957 shares at December 31, 2011 |   |   | 41 |   |   |   | 41 |   |
| Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding                                                                  |   |   | - |   |   |   | - |   |
| Additional paid-in capital                                                                                                                                       |   |   | 294,936 |   |   |   | 297,104 |   |
| Accumulated other comprehensive income                                                                                                                           |   |   | 895 |   |   |   | 984 |   |
| Accumulated deficit                                                                                                                                              |   |   | (40,795 | ) |   |   | (47,274 | ) |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Total stockholders' equity                                                                                                                                       |   |   | 255,077 |   |   |   | 250,855 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| Total liabilities and stockholders' equity                                                                                                                       |   | $ | 283,482 |   |   | $ | 282,647 |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
|                                                                                                                                                             |   |   |   |   |   |   |   |   |
| See the accompanying notes which are an integral part of these                                                                                                   |   |
| Condensed Consolidated Financial Statements.                                                                                                                     |   |

----

Table of Contents

| LUMINEX CORPORATION                                            |   |
|----------------------------------------------------------------|--------|
| CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME      |   |
| (in thousands, except per share amounts)                       |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                           |   | Three Months EndedJune 30, |   |   | Six Months EndedJune 30, |   |
|                                                           |   | 2012 |   |   | 2011 |   |   | 2012 |   |   | 2011 |   |
|                                                           |   | (unaudited) |   |   | (unaudited) |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |
| Revenue                                                        |   | $ | 48,273 |   |   | $ | 47,638 |   |   | $ | 97,000 |   |   | $ | 90,913 |   |
| Cost of revenue                                                |   |   | 13,861 |   |   |   | 13,812 |   |   |   | 28,828 |   |   |   | 26,359 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Gross profit                                                   |   |   | 34,412 |   |   |   | 33,826 |   |   |   | 68,172 |   |   |   | 64,554 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Operating expenses:                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Research and development                                       |   |   | 9,638 |   |   |   | 7,945 |   |   |   | 19,078 |   |   |   | 15,515 |   |
| Selling, general and administrative                            |   |   | 17,204 |   |   |   | 16,482 |   |   |   | 34,816 |   |   |   | 30,763 |   |
| Amortization of acquired intangible assets                     |   |   | 1,084 |   |   |   | 602 |   |   |   | 2,184 |   |   |   | 1,185 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total operating expenses                                       |   |   | 27,926 |   |   |   | 25,029 |   |   |   | 56,078 |   |   |   | 47,463 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income from operations                                         |   |   | 6,486 |   |   |   | 8,797 |   |   |   | 12,094 |   |   |   | 17,091 |   |
| Interest expense from long-term debt                           |   |   | (63 | ) |   |   | (79 | ) |   |   | (122 | ) |   |   | (162 | ) |
| Other income, net                                              |   |   | 42 |   |   |   | 108 |   |   |   | 99 |   |   |   | 215 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income before income taxes                                     |   |   | 6,465 |   |   |   | 8,826 |   |   |   | 12,071 |   |   |   | 17,144 |   |
| Income taxes                                                   |   |   | (3,513 | ) |   |   | (4,183 | ) |   |   | (5,592 | ) |   |   | (8,040 | ) |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net income                                                     |   | $ | 2,952 |   |   | $ | 4,643 |   |   | $ | 6,479 |   |   | $ | 9,104 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other comprehensive income:                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation adjustments                       |   |   | (268 | ) |   |   | 284 |   |   |   | (70 | ) |   |   | 424 |   |
| Unrealized losses on available-for-sale securities, net of tax |   |   | - |   |   |   | (1 | ) |   |   | (18 | ) |   |   | (80 | ) |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other comprehensive income (loss)                              |   |   | (268 | ) |   |   | 283 |   |   |   | (88 | ) |   |   | 344 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive income                                           |   | $ | 2,684 |   |   | $ | 4,926 |   |   | $ | 6,391 |   |   | $ | 9,448 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net income per share, basic                                    |   | $ | 0.07 |   |   | $ | 0.11 |   |   | $ | 0.16 |   |   | $ | 0.22 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shares used in computing net income per share, basic           |   |   | 41,064 |   |   |   | 41,262 |   |   |   | 40,992 |   |   |   | 41,251 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net income per share, diluted                                  |   | $ | 0.07 |   |   | $ | 0.11 |   |   | $ | 0.15 |   |   | $ | 0.21 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shares used in computing net income per share, diluted         |   |   | 42,399 |   |   |   | 42,446 |   |   |   | 42,246 |   |   |   | 42,398 |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| See the accompanying notes which are an integral part of these |   |
| Condensed Consolidated Financial Statements.                   |   |

----

Table of Contents

| LUMINEX CORPORATION                                                               |   |
|-----------------------------------------------------------------------------------|--------|
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS                                   |   |
| (in thousands)                                                                    |   |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                              |   | Three Months EndedJune 30, |   |   | Six Months EndedJune 30, |   |
|                                                                              |   | 2012 |   |   | 2011 |   |   | 2012 |   |   | 2011 |   |
|                                                                              |   | (unaudited) |   |   | (unaudited) |   |
| Cash flows from operating activities:                                             |   |   |   |   |   |   |   |   |   |   |   |   |
| Net income                                                                        |   | $ | 2,952 |   |   | $ | 4,643 |   |   | $ | 6,479 |   |   | $ | 9,104 |   |
| Adjustments to reconcile net income to net cash provided by operating activities: |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Depreciation and amortization                                                     |   |   | 3,533 |   |   |   | 2,622 |   |   |   | 7,055 |   |   |   | 5,138 |   |
| Stock-based compensation                                                          |   |   | 2,571 |   |   |   | 2,993 |   |   |   | 5,214 |   |   |   | 5,540 |   |
| Deferred income tax benefit                                                       |   |   | 376 |   |   |   | 2,054 |   |   |   | 929 |   |   |   | 3,379 |   |
| Excess income tax benefit from employee stock-based awards                        |   |   | (2,476 | ) |   |   | (1,501 | ) |   |   | (2,773 | ) |   |   | (3,705 | ) |
| Other                                                                             |   |   | (49 | ) |   |   | 234 |   |   |   | 183 |   |   |   | 305 |   |
| Changes in operating assets and liabilities:                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Accounts receivable, net                                                          |   |   | 830 |   |   |   | 68 |   |   |   | (3,183 | ) |   |   | 6,656 |   |
| Inventories, net                                                                  |   |   | (1,860 | ) |   |   | 1,793 |   |   |   | (1,727 | ) |   |   | 1,207 |   |
| Other assets                                                                      |   |   | (1,671 | ) |   |   | (164 | ) |   |   | (1,631 | ) |   |   | (1,186 | ) |
| Accounts payable                                                                  |   |   | 555 |   |   |   | (1,510 | ) |   |   | 69 |   |   |   | (4,254 | ) |
| Accrued liabilities                                                               |   |   | 4,811 |   |   |   | 1,953 |   |   |   | (1,215 | ) |   |   | 167 |   |
| Deferred revenue                                                                  |   |   | (50 | ) |   |   | (317 | ) |   |   | 93 |   |   |   | (460 | ) |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net cash provided by operating activities                                         |   |   | 9,522 |   |   |   | 12,868 |   |   |   | 9,493 |   |   |   | 21,891 |   |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Cash flows from investing activities:                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Purchases of available-for-sale securities                                        |   |   | (1,496 | ) |   |   | (22,201 | ) |   |   | (10,495 | ) |   |   | (29,247 | ) |
| Sales and maturities of available-for-sale securities                             |   |   | 21,490 |   |   |   | 7,256 |   |   |   | 30,005 |   |   |   | 14,177 |   |
| Purchase of property and equipment                                                |   |   | (3,761 | ) |   |   | (2,644 | ) |   |   | (5,357 | ) |   |   | (3,798 | ) |
| Business acquisition consideration, net of cash acquired                          |   |   | - |   |   |   | (33,914 | ) |   |   | - |   |   |   | (33,914 | ) |
| Purchase of cost method investment                                                |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (2,000 | ) |
| Acquired technology rights                                                        |   |   | (291 | ) |   |   | (87 | ) |   |   | (291 | ) |   |   | (87 | ) |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net cash provided by (used in) investing activities                               |   |   | 15,942 |   |   |   | (51,590 | ) |   |   | 13,862 |   |   |   | (54,869 | ) |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Cash flows from financing activities:                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Payments on debt                                                                  |   |   | (1,025 | ) |   |   | (885 | ) |   |   | (1,025 | ) |   |   | (885 | ) |
| Proceeds from issuance of common stock                                            |   |   | 1,706 |   |   |   | 590 |   |   |   | 2,363 |   |   |   | 818 |   |
| Payments for stock repurchases                                                    |   |   | (4,432 | ) |   |   | (1,436 | ) |   |   | (9,880 | ) |   |   | (4,686 | ) |
| Excess income tax benefit from employee stock-based awards                        |   |   | 2,476 |   |   |   | 1,501 |   |   |   | 2,773 |   |   |   | 3,705 |   |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net cash used in financing activities                                             |   |   | (1,275 | ) |   |   | (230 | ) |   |   | (5,769 | ) |   |   | (1,048 | ) |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Effect of foreign currency exchange rate on cash                                  |   |   | (121 | ) |   |   | 1 |   |   |   | 30 |   |   |   | 149 |   |
| Change in cash and cash equivalents                                               |   |   | 24,068 |   |   |   | (38,951 | ) |   |   | 17,616 |   |   |   | (33,877 | ) |
| Cash and cash equivalents, beginning of period                                    |   |   | 51,830 |   |   |   | 94,561 |   |   |   | 58,282 |   |   |   | 89,487 |   |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Cash and cash equivalents, end of period                                          |   | $ | 75,898 |   |   | $ | 55,610 |   |   | $ | 75,898 |   |   | $ | 55,610 |   |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| See the accompanying notes which are an integral part of these                    |   |
| Condensed Consolidated Financial Statements.                                      |   |

----

Table of Contents

NOTE 

----

Table of Contents

|                                     |   | Amortized Cost |   |   | Gains in Accumulated Other Comprehensive Income |   |   | Losses in Accumulated Other Comprehensive Income |   |   | Estimated Fair Value |   |
|------------------------------------------|--------|----------------|--------|--------|-------------------------------------------------|--------|--------|--------------------------------------------------|--------|--------|----------------------|--------|
|                                     |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |
| Current:                                 |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |
| Money Market funds                       |   | $              | 55,698 |   |                                            | $      | -      |                                             |   | $      | -                    |   |   | $ | 55,698 |   |
| Non-government sponsored debt securities |   |           | 23,133 |   |                                            |   | 20     |                                             |   |   | (3                   | )      |   |   | 23,150 |   |
| Total current securities                 |   |           | 78,831 |   |                                            |   | 20     |                                             |   |   | (3                   | )      |   |   | 78,848 |   |
|                                     |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |   |   |   |   |
| Noncurrent:                              |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |   |   |   |   |
| Non-government sponsored debt securities |   |           | 6,000  |   |                                            |   | -      |                                             |   |   | (3                   | )      |   |   | 5,997 |   |
| Total noncurrent securities              |   |           | 6,000  |   |                                            |   | -      |                                             |   |   | (3                   | )      |   |   | 5,997 |   |
|                                     |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |   |   |   |   |
| Total available-for-sale securities      |   | $              | 84,831 |   |                                            | $      | 20     |                                             |   | $      | (6                   | )      |   | $ | 84,845 |   |

|                                     |   | Amortized Cost |   |   | Gains in Accumulated Other Comprehensive Income |   |   | Losses in Accumulated Other Comprehensive Income |   |   | Estimated Fair Value |   |
|------------------------------------------|--------|----------------|--------|--------|-------------------------------------------------|--------|--------|--------------------------------------------------|--------|--------|----------------------|--------|
|                                     |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |
| Current:                                 |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |
| Money Market funds                       |   | $              | 38,520 |   |                                            | $      | -      |                                             |   | $      | -                    |   |   | $ | 38,520 |   |
| Non-government sponsored debt securities |   |           | 42,554 |   |                                            |   | 32     |                                             |   |   | (12                  | )      |   |   | 42,574 |   |
| Total current securities                 |   |           | 81,074 |   |                                            |   | 32     |                                             |   |   | (12                  | )      |   |   | 81,094 |   |
|                                     |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |   |   |   |   |
| Noncurrent:                              |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |   |   |   |   |
| Non-government sponsored debt securities |   |           | 6,129  |   |                                            |   | 22     |                                             |   |   | -                    |   |   |   | 6,151 |   |
| Total noncurrent securities              |   |           | 6,129  |   |                                            |   | 22     |                                             |   |   | -                    |   |   |   | 6,151 |   |
|                                     |   |           |   |   |                                            |   |   |                                             |   |   |                 |   |   |   |   |   |
| Total available-for-sale securities      |   | $              | 87,203 |   |                                            | $      | 54     |                                             |   | $      | (12                  | )      |   | $ | 87,245 |   |

|                                 |   | Estimated Fair Value |   |
|--------------------------------------|--------|----------------------|--------|
|                                 |   | June 30, 2012        |   |   | December 31, 2011 |   |
| Due in one year or less              |   | $                    | 23,150 |   |   | $ | 42,574 |   |
| Due after one year through two years |   |                 | 5,997  |   |   |   | 6,151 |   |
|                                 |   | $                    | 29,147 |   |   | $ | 48,725 |   |

----

Table of Contents

|               |   | June 30, 2012 |   |   | December 31, 2011 |   |
|--------------------|--------|---------------|--------|--------|-------------------|--------|
| Parts and supplies |   | $             | 14,397 |   |              | $      | 12,382 |   |
| Work-in-progress   |   |          | 4,867  |   |              |   | 6,829 |   |
| Finished goods     |   |          | 7,040  |   |              |   | 5,368 |   |
|               |   | $             | 26,304 |   |              | $      | 24,579 |   |

----

Table of Contents

|                                     |   | Fair Value Measurements at June 30, 2012 Using |   |
|------------------------------------------|--------|------------------------------------------------|--------|
|                                     |   | Level 1                                        |   |   | Level 2 |   |   | Level 3 |   |   | Total |   |
| Assets:                                  |   |                                           |   |   |   |   |   |   |   |   |   |   |
| Money Market funds                       |   | $                                              | 55,698 |   |   | $ | - |   |   | $ | - |   |   | $ | 55,698 |   |
| Non-government sponsored debt securities |   |                                           | -      |   |   |   | 29,147 |   |   |   | - |   |   |   | 29,147 |   |
| Cost-method equity investment            |   |                                           | -      |   |   |   | - |   |   |   | 4,081 |   |   |   | 4,081 |   |
|                                     |   |                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Liabilities:                             |   |                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Long-term debt                           |   | $                                              | -      |   |   | $ | - |   |   | $ | 2,352 |   |   | $ | 2,352 |   |

|                                     |   | Fair Value Measurements at December 31, 2011 Using |   |
|------------------------------------------|--------|----------------------------------------------------|--------|
|                                     |   | Level 1                                            |   |   | Level 2 |   |   | Level 3 |   |   | Total |   |
| Assets:                                  |   |                                               |   |   |   |   |   |   |   |   |   |   |
| Money Market funds                       |   | $                                                  | 38,520 |   |   | $ | - |   |   | $ | - |   |   | $ | 38,520 |   |
| Non-government sponsored debt securities |   |                                               | -      |   |   |   | 48,725 |   |   |   | - |   |   |   | 48,725 |   |
| Cost-method equity investment            |   |                                               | -      |   |   |   | - |   |   |   | 4,081 |   |   |   | 4,081 |   |
|                                     |   |                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Liabilities:                             |   |                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Long-term debt                           |   | $                                                  | -      |   |   | $ | - |   |   | $ | 3,232 |   |   | $ | 3,232 |   |

|                                     |   | June 30, 2012 |   |   | December 31, 2011 |   |
|------------------------------------------|--------|---------------|--------|--------|-------------------|--------|
| Balance at beginning of year             |   | $             | 42,763 |   |              | $      | 42,250 |   |
| Acquisition of EraGen                    |   |          | -      |   |              |   | 532 |   |
| Foreign currency translation adjustments |   |          | (5     | )      |              |   | (19 | ) |
| Balance at end of period                 |   | $             | 42,758 |   |              | $      | 42,763 |   |

----

Table of Contents

|                                                  |   | Finite-lived                           |    |   | Indefinite-lived             |   |   |                                 |   |
|-------------------------------------------------------|--------|----------------------------------------|---------|--------|------------------------------|--------|--------|--------------------------------------|--------|
|                                                  |   | Technology, trade secrets and know-how |    |   | Customer lists and contracts |   |   | Other identifiable intangible assets |   |   | IP R&D |   |   | Total |   |
| 2011                                                  |   |                                   |    |   |                         |   |   |                                 |   |   |   |   |   |   |   |
| Balance at December 31, 2010                          |   | $                                      | 18,407  |   |                         | $      | 1,285  |                                 |   | $ | 283 |   |   | $ | 712 |   |   | $ | 20,687 |   |
| Additions due to acquisition of LMA                   |   |                                   | 11,332  |   |                         |   | 6,697  |                                 |   |   | 1,652 |   |   |   | 286 |   |   |   | 19,967 |   |
| Completion of IP R&D projects                     |   |                                   | 270     |   |                         |   | -      |                                 |   |   | - |   |   |   | (270 | ) |   |   | - |   |
| Write-off of IP R&D projects                      |   |                                   | -       |   |                         |   | -      |                                 |   |   | - |   |   |   | (92 | ) |   |   | (92 | ) |
| Foreign currency translation adjustments              |   |                                   | (9      | )      |                         |   | (1     | )                                    |   |   | (2 | ) |   |   | (5 | ) |   |   | (17 | ) |
| Balance at December 31, 2011                          |   |                                   | 30,000  |   |                         |   | 7,981  |                                 |   |   | 1,933 |   |   |   | 631 |   |   |   | 40,545 |   |
| Less: accumulated amortization:                       |   |                                   |    |   |                         |   |   |                                 |   |   |   |   |   |   |   |   |   |   |   |   |
| Accumulated amortization balance at December 31, 2010 |   |                                   | (7,362  | )      |                         |   | (308   | )                                    |   |   | (73 | ) |   |   | - |   |   |   | (7,743 | ) |
| Amortization expense                                  |   |                                   | (2,643  | )      |                         |   | (461   | )                                    |   |   | (272 | ) |   |   | - |   |   |   | (3,376 | ) |
| Foreign currency translation adjustments              |   |                                   | 6       |   |                         |   | 1      |                                 |   |   | 4 |   |   |   | - |   |   |   | 11 |   |
| Accumulated amortization balance at December 31, 2011 |   |                                   | (9,999  | )      |                         |   | (768   | )                                    |   |   | (341 | ) |   |   | - |   |   |   | (11,108 | ) |
| Net balance at December 31, 2011                      |   | $                                      | 20,001  |   |                         | $      | 7,213  |                                 |   | $ | 1,592 |   |   | $ | 631 |   |   | $ | 29,437 |   |
|                                                  |   |                                   |    |   |                         |   |   |                                 |   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average life (in years)                      |   |                                   | 10      |   |                         |   | 11     |                                 |   |   | 9 |   |   |   |   |   |   |   |   |   |
|                                                  |   |                                   |    |   |                         |   |   |                                 |   |   |   |   |   |   |   |   |   |   |   |   |
| 2012                                                  |   |                                   |    |   |                         |   |   |                                 |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2011                          |   | $                                      | 30,000  |   |                         | $      | 7,981  |                                 |   | $ | 1,933 |   |   | $ | 631 |   |   | $ | 40,545 |   |
| Foreign currency translation adjustments              |   |                                   | -       |   |                         |   | -      |                                 |   |   | (1 | ) |   |   | (3 | ) |   |   | (4 | ) |
| Balance at June 30, 2012                              |   |                                   | 30,000  |   |                         |   | 7,981  |                                 |   |   | 1,932 |   |   |   | 628 |   |   |   | 40,541 |   |
| Less: accumulated amortization:                       |   |                                   |    |   |                         |   |   |                                 |   |   |   |   |   |   |   |   |   |   |   |   |
| Accumulated amortization balance at December 31, 2011 |   |                                   | (9,999  | )      |                         |   | (768   | )                                    |   |   | (341 | ) |   |   | - |   |   |   | (11,108 | ) |
| Amortization expense                                  |   |                                   | (1,593  | )      |                         |   | (395   | )                                    |   |   | (196 | ) |   |   | - |   |   |   | (2,184 | ) |
| Foreign currency translation adjustments              |   |                                   | 4       |   |                         |   | 1      |                                 |   |   | 2 |   |   |   | - |   |   |   | 7 |   |
| Accumulated amortization balance at June 30, 2012     |   |                                   | (11,588 | )      |                         |   | (1,162 | )                                    |   |   | (535 | ) |   |   | - |   |   |   | (13,285 | ) |
| Net balance at June 30, 2012                          |   | $                                      | 18,412  |   |                         | $      | 6,819  |                                 |   | $ | 1,397 |   |   | $ | 628 |   |   | $ | 27,256 |   |
|                                                  |   |                                   |    |   |                         |   |   |                                 |   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average life (in years)                      |   |                                   | 10      |   |                         |   | 11     |                                 |   |   | 9 |   |   |   |   |   |   |   |   |   |

----

Table of Contents

| 2012 (six months) |   | $      | 2,058  |   |
|-------------------|--------|--------|--------|--------|
| 2013              |   |   | 4,109  |   |
| 2014              |   |   | 4,082  |   |
| 2015              |   |   | 3,318  |   |
| 2016              |   |   | 3,107  |   |
| Thereafter        |   |   | 9,954  |   |
|              |   |   | 26,628 |   |
| IP R&D        |   |   | 628    |   |
|              |   | $      | 27,256 |   |

|                                                                                         |   | Three Months EndedJune 30, |   |   | Six Months EndedJune 30, |   |
|----------------------------------------------------------------------------------------------|--------|----------------------------|--------|--------|--------------------------|--------|
|                                                                                         |   | 2012                       |   |   | 2011                     |   |   | 2012 |   |   | 2011 |   |
| Numerator:                                                                                   |   |                       |   |   |                     |   |   |   |   |   |   |   |
| Net income                                                                                   |   | $                          | 2,952  |   |                     | $      | 4,643 |   |   | $ | 6,479 |   |   | $ | 9,104 |   |
|                                                                                         |   |                       |   |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Denominator:                                                                                 |   |                       |   |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Denominator for basic net income per share - weighted average common stock outstanding       |   |                       | 41,064 |   |                     |   | 41,262 |   |   |   | 40,992 |   |   |   | 41,251 |   |
|                                                                                         |   |                       |   |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Effect of dilutive securities: stock options and awards                                      |   |                       | 1,335  |   |                     |   | 1,184 |   |   |   | 1,254 |   |   |   | 1,147 |   |
|                                                                                         |   |                       |   |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Denominator for diluted net income per share - weighted average shares outstanding - diluted |   |                       | 42,399 |   |                     |   | 42,446 |   |   |   | 42,246 |   |   |   | 42,398 |   |
|                                                                                         |   |                       |   |   |                     |   |   |   |   |   |   |   |   |   |   |   |
| Basic net income per share                                                                   |   | $                          | 0.07   |   |                     | $      | 0.11 |   |   | $ | 0.16 |   |   | $ | 0.22 |   |
| Diluted net income per share                                                                 |   | $                          | 0.07   |   |                     | $      | 0.11 |   |   | $ | 0.15 |   |   | $ | 0.21 |   |

----

Table of Contents

| Stock Options                    |   | Shares(in thousands) |   |   | Weighted Average Exercise Price |   |
|----------------------------------|--------|----------------------|--------|--------|---------------------------------|--------|
| Outstanding at December 31, 2011 |   |                 | 2,020  |   |                            | $      | 10.19 |   |
| Granted                          |   |                 | 153    |   |                            |   | 22.68 |   |
| Exercised                        |   |                 | (319   | )      |                            |   | 7.40 |   |
| Cancelled or expired             |   |                 | -      |   |                            |   | - |   |
| Outstanding at June 30, 2012     |   |                 | 1,854  |   |                            | $      | 11.70 |   |

| Restricted Stock Awards         |   | Shares(in thousands) |   |   | Weighted Average Grant Price |   |
|---------------------------------|--------|----------------------|--------|--------|------------------------------|--------|
| Non-vested at December 31, 2011 |   |                 | 903    |   |                         | $      | 17.13 |   |
| Granted                         |   |                 | 314    |   |                         |   | 22.68 |   |
| Vested                          |   |                 | (261   | )      |                         |   | 17.22 |   |
| Cancelled or expired            |   |                 | (25    | )      |                         |   | 17.43 |   |
| Non-vested at June 30, 2012     |   |                 | 931    |   |                         | $      | 18.97 |   |
|                            |   |                 |   |   |                         |   |   |   |
|                            |   |                 |   |   |                         |   |   |   |
|                            |   |                 |   |   |                         |   |   |   |
| Restricted Stock Units          |   | Shares(in thousands) |   |   |                         |   |   |
| Non-vested at December 31, 2011 |   |                 | 827    |   |                         |   |   |   |
| Granted                         |   |                 | 243    |   |                         |   |   |   |
| Vested                          |   |                 | (77    | )      |                         |   |   |   |
| Cancelled or expired            |   |                 | (103   | )      |                         |   |   |   |
| Non-vested at June 30, 2012     |   |                 | 890    |   |                         |   |   |   |

|                                                   |   | Three Months EndedJune 30, |   |   | Six Months EndedJune 30, |   |
|--------------------------------------------------------|--------|----------------------------|--------|--------|--------------------------|--------|
|                                                   |   | 2012                       |   |   | 2011                     |   |   | 2012 |   |   | 2011 |   |
| Cost of revenue                                        |   | $                          | 246    |   |                     | $      | 225 |   |   | $ | 475 |   |   | $ | 443 |   |
| Research and development                               |   |                       | 472    |   |                     |   | 536 |   |   |   | 988 |   |   |   | 1,030 |   |
| Selling, general and administrative                    |   |                       | 1,853  |   |                     |   | 2,232 |   |   |   | 3,751 |   |   |   | 4,067 |   |
| Stock-based compensation costs reflected in net income |   | $                          | 2,571  |   |                     | $      | 2,993 |   |   | $ | 5,214 |   |   | $ | 5,540 |   |

----

Table of Contents

|                             |   | Three Months EndedJune 30, 2012 |    |   | Three Months EndedJune 30, 2011 |   |
|----------------------------------|--------|---------------------------------|---------|--------|---------------------------------|--------|
|                             |   | TSP Segment                     |    |   | ARP Segment                     |   |   | Consolidated |   |   | TSP Segment |   |   | ARP Segment |   |   | Consolidated |   |
|                             |   |                            |    |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Revenues from external customers |   | $                               | 29,565  |   |                            | $      | 18,708 |   |   | $ | 48,273 |   |   | $ | 36,211 |   |   | $ | 11,427 |   |   | $ | 47,638 |   |
|                             |   |                            |    |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Depreciation and amortization    |   |                            | 1,675   |   |                            |   | 1,858 |   |   | $ | 3,533 |   |   |   | 1,487 |   |   |   | 1,135 |   |   | $ | 2,622 |   |
|                             |   |                            |    |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Operating profit (loss)          |   |                            | 4,342   |   |                            |   | 2,144 |   |   | $ | 6,486 |   |   |   | 11,572 |   |   |   | (2,775 | ) |   | $ | 8,797 |   |
|                             |   |                            |    |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Segment assets                   |   |                            | 167,015 |   |                            |   | 116,467 |   |   | $ | 283,482 |   |   |   | 152,994 |   |   |   | 120,432 |   |   | $ | 273,426 |   |

|                             |   | Six Months EndedJune 30, 2012 |    |   | Six Months EndedJune 30, 2011 |   |
|----------------------------------|--------|-------------------------------|---------|--------|-------------------------------|--------|
|                             |   | TSP Segment                   |    |   | ARP Segment                   |   |   | Consolidated |   |   | TSP Segment |   |   | ARP Segment |   |   | Consolidated |   |
|                             |   |                          |    |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Revenues from external customers |   | $                             | 59,774  |   |                          | $      | 37,226 |   |   | $ | 97,000 |   |   | $ | 68,146 |   |   | $ | 22,767 |   |   | $ | 90,913 |   |
|                             |   |                          |    |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Depreciation and amortization    |   |                          | 3,295   |   |                          |   | 3,760 |   |   | $ | 7,055 |   |   |   | 2,902 |   |   |   | 2,236 |   |   | $ | 5,138 |   |
|                             |   |                          |    |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Operating profit (loss)          |   |                          | 8,541   |   |                          |   | 3,553 |   |   | $ | 12,094 |   |   |   | 20,228 |   |   |   | (3,137 | ) |   | $ | 17,091 |   |
|                             |   |                          |    |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Segment assets                   |   |                          | 167,015 |   |                          |   | 116,467 |   |   | $ | 283,482 |   |   |   | 152,994 |   |   |   | 120,432 |   |   | $ | 273,426 |   |

|                                        |   |   |   |
|---------------------------------------------|--------|--------|--------|
| Accrued warranty costs at December 31, 2011 |   | $      | 681    |   |
| Warranty expenses                           |   |   | (523   | ) |
| Accrual for warranty costs                  |   |   | 544    |   |
| Accrued warranty costs at June 30, 2012     |   | $      | 702    |   |

----

Table of Contents

----

Table of Contents

ITEM

| ·   | risks and uncertainties relating to market demand and acceptance of our products and technology; |
|--------------------|--------------------------------------------------------------------------------------------------|

| ·   | dependence on strategic partners for development, commercialization and distribution of products; |
|--------------------|---------------------------------------------------------------------------------------------------|

| ·   | concentration of our revenue in a limited number of strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating our technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | the impact of the ongoing uncertainty in U.S. and global finance markets and changes in government funding, including its effects on the capital spending policies of our partners and end users and their ability to finance purchases of our products; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, fluctuations in bulk purchases of consumables, fluctuations in product mix, and the seasonal nature of some of our assay products; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | our ability to obtain and enforce intellectual property protections on our products and technologies; |
|--------------------|-------------------------------------------------------------------------------------------------------|

| ·   | reliance on third party distributors for distribution of specific assay products; |
|--------------------|-----------------------------------------------------------------------------------|

| ·   | our ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels; |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| ·   | potential shortages, or increases in costs, of components or other disruptions to our manufacturing operations; |
|--------------------|-----------------------------------------------------------------------------------------------------------------|

| ·   | competition; |
|--------------------|--------------|

| ·   | our ability to successfully launch new products; |
|--------------------|--------------------------------------------------|

| ·   | the timing of and process for regulatory approvals; |
|--------------------|-----------------------------------------------------|

| ·   | our increasing dependency on information technology to enable us to improve the effectiveness of our operations and to monitor financial accuracy and efficiency; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | the implementation, including any modification, of our strategic operating plans; |
|--------------------|-----------------------------------------------------------------------------------|

| ·   | the uncertainty regarding the outcome or expense of any litigation brought against or initiated by us; |
|--------------------|--------------------------------------------------------------------------------------------------------|

| ·   | risks relating to our foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies; and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ·   | risks and uncertainties associated with implementing our acquisition strategy, including our ability to obtain financing, our ability to integrate acquired companies or selected assets into our consolidated business operations, and the ability to recognize the benefits of our acquisitions. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ·   | System revenue is generated from the sale of our xMAP multiplexing analyzers and peripherals and automated punching instruments. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------|

| ·   | Consumable revenue is generated from the sale of our dyed polystyrene microspheres and sheath fluid.  Our larger commercial and development partners often purchase these consumables in bulk to minimize the number of incoming qualification events and to allow for longer development and production runs. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Royalty revenue is generated when a partner sells our proprietary microspheres to an end user, a partner sells a kit incorporating our proprietary technologies to an end user, or a partner utilizes a kit incorporating our proprietary technologies to provide a testing result to a user.  End users can be facilities such as testing labs, development facilities and research facilities that buy prepared kits and have specific testing needs or testing service companies that provide assay results to pharmaceutical research companies or physicians. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Assay revenue is generated from the sale of our kits, which are a combination of chemical and biological reagents, and our proprietary technologies used to perform diagnostic and research assays on samples. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Service revenue is generated when a partner or other owner of a system purchases a service contract from us after the standard warranty has expired or pays us for our time and materials to service instruments.  Service contract revenue is amortized over the life of the contract and the costs associated with those contracts are recognized as incurred. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Other revenue consists of items such as training, shipping, parts sales, license revenue, grant revenue, contract research and development fees, milestone revenue and other items that individually amount to less than 5% of total revenue. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Consolidated revenue was $48.3 million for the quarter ended June 30, 2012, representing a 1% increase over revenue for the second quarter of 2011. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Shipments of 278 multiplexing analyzers that included 167 MAGPIX systems, resulting in cumulative life-to-date multiplexing analyzer shipments of 9,162, up 12% from a year ago. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Assay revenue was $17.5 million, an 89% increase over the second quarter of 2011. |
|--------------------|-----------------------------------------------------------------------------------|

| ·   | Operating expenses were $27.9 million for the quarter ended June 30, 2012, an increase of $2.9 million over the quarter ended June 30, 2011, including $0.9 million of incremental operating expenses from LMA. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Received CE marking of both the xMAP NeoPlex4® Assay and NeoPlex® System in April, 2012.  This system changes the way newborn screening is performed, providing four assays from one blood spot punch, reducing sample requirements and improving laboratory efficiency. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ·   | maintenance and  improvement of our existing products and the timely development, completion and successful commercial launch of our pipeline products; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | commercialization, regulatory clearance and market adoption of output from the ARP segment, including the NeoPlex System, NeoPlex4 Assay, CYP2C19, Gastrointestinal Pathogen Panel (“GPP”), and the related clearance of our MAGPIX and FM3D instruments; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | the expansion and enhancement of our installed base and our market position within our identified target market segments; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------|

| ·   | the effect of the ongoing uncertainty in global finance markets and changes in government funding on planned purchases by end users; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------|

| ·   | the continued adoption and development of partner products incorporating Luminex technology through effective partner management; and |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------|

| ·   | development of the next generation sample-to-answer platform for our MultiCode RTx technology. |
|--------------------|------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|                           |   | Three Months EndedJune 30, |   |   |   |   |   |     |   |
|--------------------------------|--------|----------------------------|--------|--------|--------|--------|--------|----------|--------|
|                           |   | 2012                       |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| Revenue                        |   | $                          | 48,273 |   |   | $      | 47,638 |     |   | $ | 635 |   |   |   | 1 | % |
| Gross profit                   |   | $                          | 34,412 |   |   | $      | 33,826 |     |   |   | 586 |   |   |   | 2 | % |
| Gross profit margin percentage |   |                       | 71     | %      |   |   | 71     | %        |   |   | 0 | % |   |   | N/A |   |
| Operating expenses             |   | $                          | 27,926 |   |   | $      | 25,029 |     |   |   | 2,897 |   |   |   | 12 | % |
| Income from operations         |   | $                          | 6,486  |   |   | $      | 8,797  |     |   |   | (2,311 | ) |   |   | -26 | % |

|             |   | Three Months EndedJune 30, |   |   |   |   |   |     |   |
|------------------|--------|----------------------------|--------|--------|--------|--------|--------|----------|--------|
|             |   | 2012                       |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| System sales     |   | $                          | 8,386  |   |   | $      | 9,135  |     |   | $ | (749 | ) |   |   | -8 | % |
| Consumable sales |   |                       | 10,802 |   |   |   | 18,397 |     |   |   | (7,595 | ) |   |   | -41 | % |
| Royalty revenue  |   |                       | 7,715  |   |   |   | 7,412  |     |   |   | 303 |   |   |   | 4 | % |
| Assay revenue    |   |                       | 17,510 |   |   |   | 9,261  |     |   |   | 8,249 |   |   |   | 89 | % |
| Service revenue  |   |                       | 1,970  |   |   |   | 1,844  |     |   |   | 126 |   |   |   | 7 | % |
| Other revenue    |   |                       | 1,890  |   |   |   | 1,589  |     |   |   | 301 |   |   |   | 19 | % |
|             |   | $                          | 48,273 |   |   | $      | 47,638 |     |   | $ | 635 |   |   |   | 1 | % |

----

Table of Contents

|                           |   | Three Months EndedJune 30, |   |   |   |   |   |     |   |
|--------------------------------|--------|----------------------------|--------|--------|--------|--------|--------|----------|--------|
|                           |   | 2012                       |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| Revenue                        |   | $                          | 29,565 |   |   | $      | 36,211 |     |   | $ | (6,646 | ) |   |   | -18 | % |
| Gross profit                   |   | $                          | 20,090 |   |   | $      | 26,905 |     |   |   | (6,815 | ) |   |   | -25 | % |
| Gross profit margin percentage |   |                       | 68     | %      |   |   | 74     | %        |   |   | -6 | % |   |   | N/A |   |
| Operating expenses             |   | $                          | 15,748 |   |   | $      | 15,333 |     |   |   | 415 |   |   |   | 3 | % |
| Income from operations         |   | $                          | 4,342  |   |   | $      | 11,572 |     |   |   | (7,230 | ) |   |   | -62 | % |

|             |   | Three Months EndedJune 30, |   |   |   |   |   |     |   |
|------------------|--------|----------------------------|--------|--------|--------|--------|--------|----------|--------|
|             |   | 2012                       |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| System sales     |   | $                          | 7,734  |   |   | $      | 7,437  |     |   | $ | 297 |   |   |   | 4 | % |
| Consumable sales |   |                       | 10,736 |   |   |   | 18,264 |     |   |   | (7,528 | ) |   |   | -41 | % |
| Royalty revenue  |   |                       | 7,588  |   |   |   | 7,408  |     |   |   | 180 |   |   |   | 2 | % |
| Service revenue  |   |                       | 1,827  |   |   |   | 1,722  |     |   |   | 105 |   |   |   | 6 | % |
| Other revenue    |   |                       | 1,680  |   |   |   | 1,380  |     |   |   | 300 |   |   |   | 22 | % |
|             |   | $                          | 29,565 |   |   | $      | 36,211 |     |   | $ | (6,646 | ) |   |   | -18 | % |

----

Table of Contents

|                           |   | Three Months EndedJune 30, |   |   |   |   |   |     |   |
|--------------------------------|--------|----------------------------|--------|--------|--------|--------|--------|----------|--------|
|                           |   | 2012                       |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| Revenue                        |   | $                          | 18,708 |   |   | $      | 11,427 |     |   | $ | 7,281 |   |   |   | 64 | % |
| Gross profit                   |   | $                          | 14,322 |   |   | $      | 6,921  |     |   |   | 7,401 |   |   |   | 107 | % |
| Gross profit margin percentage |   |                       | 77     | %      |   |   | 61     | %        |   |   | 16 | % |   |   | N/A |   |
| Operating expenses             |   | $                          | 12,178 |   |   | $      | 9,696  |     |   |   | 2,482 |   |   |   | 26 | % |
| Income (loss) from operations  |   | $                          | 2,144  |   |   | $      | (2,775 | )        |   |   | 4,919 |   |   |   | 177 | % |

----

Table of Contents

|             |   | Three Months EndedJune 30, |   |   |   |   |   |     |   |
|------------------|--------|----------------------------|--------|--------|--------|--------|--------|----------|--------|
|             |   | 2012                       |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| System sales     |   | $                          | 652    |   |   | $      | 1,698  |     |   | $ | (1,046 | ) |   |   | -62 | % |
| Consumable sales |   |                       | 66     |   |   |   | 133    |     |   |   | (67 | ) |   |   | -50 | % |
| Royalty revenue  |   |                       | 127    |   |   |   | 4      |     |   |   | 123 |   |   |   | 3075 | % |
| Assay revenue    |   |                       | 17,510 |   |   |   | 9,261  |     |   |   | 8,249 |   |   |   | 89 | % |
| Service revenue  |   |                       | 143    |   |   |   | 122    |     |   |   | 21 |   |   |   | 17 | % |
| Other revenue    |   |                       | 210    |   |   |   | 209    |     |   |   | 1 |   |   |   | 0 | % |
|             |   | $                          | 18,708 |   |   | $      | 11,427 |     |   | $ | 7,281 |   |   |   | 64 | % |

----

Table of Contents

|                           |   | Six Months EndedJune 30, |   |   |   |   |   |     |   |
|--------------------------------|--------|--------------------------|--------|--------|--------|--------|--------|----------|--------|
|                           |   | 2012                     |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| Revenue                        |   | $                        | 97,000 |   |   | $      | 90,913 |     |   | $ | 6,087 |   |   |   | 7 | % |
| Gross profit                   |   | $                        | 68,172 |   |   | $      | 64,554 |     |   |   | 3,618 |   |   |   | 6 | % |
| Gross profit margin percentage |   |                     | 70     | %      |   |   | 71     | %        |   |   | -1 | % |   |   | N/A |   |
| Operating expenses             |   | $                        | 56,078 |   |   | $      | 47,463 |     |   |   | 8,615 |   |   |   | 18 | % |
| Income from operations         |   | $                        | 12,094 |   |   | $      | 17,091 |     |   |   | (4,997 | ) |   |   | -29 | % |

|             |   | Six Months EndedJune 30, |   |   |   |   |   |     |   |
|------------------|--------|--------------------------|--------|--------|--------|--------|--------|----------|--------|
|             |   | 2012                     |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| System sales     |   | $                        | 15,384 |   |   | $      | 16,814 |     |   | $ | (1,430 | ) |   |   | -9 | % |
| Consumable sales |   |                     | 22,702 |   |   |   | 33,399 |     |   |   | (10,697 | ) |   |   | -32 | % |
| Royalty revenue  |   |                     | 15,957 |   |   |   | 14,668 |     |   |   | 1,289 |   |   |   | 9 | % |
| Assay revenue    |   |                     | 34,807 |   |   |   | 18,845 |     |   |   | 15,962 |   |   |   | 85 | % |
| Service revenue  |   |                     | 3,894  |   |   |   | 3,673  |     |   |   | 221 |   |   |   | 6 | % |
| Other revenue    |   |                     | 4,256  |   |   |   | 3,514  |     |   |   | 742 |   |   |   | 21 | % |
|             |   | $                        | 97,000 |   |   | $      | 90,913 |     |   | $ | 6,087 |   |   |   | 7 | % |

----

Table of Contents

|                           |   | Six Months EndedJune 30, |   |   |   |   |   |     |   |
|--------------------------------|--------|--------------------------|--------|--------|--------|--------|--------|----------|--------|
|                           |   | 2012                     |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| Revenue                        |   | $                        | 59,774 |   |   | $      | 68,146 |     |   | $ | (8,372 | ) |   |   | -12 | % |
| Gross profit                   |   | $                        | 41,466 |   |   | $      | 50,286 |     |   |   | (8,820 | ) |   |   | -18 | % |
| Gross profit margin percentage |   |                     | 69     | %      |   |   | 74     | %        |   |   | -5 | % |   |   | N/A |   |
| Operating expenses             |   | $                        | 32,925 |   |   | $      | 30,058 |     |   |   | 2,867 |   |   |   | 10 | % |
| Income from operations         |   | $                        | 8,541  |   |   | $      | 20,228 |     |   |   | (11,687 | ) |   |   | -58 | % |

|             |   | Six Months EndedJune 30, |   |   |   |   |   |     |   |
|------------------|--------|--------------------------|--------|--------|--------|--------|--------|----------|--------|
|             |   | 2012                     |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| System sales     |   | $                        | 14,038 |   |   | $      | 13,833 |     |   | $ | 205 |   |   |   | 1 | % |
| Consumable sales |   |                     | 22,564 |   |   |   | 33,238 |     |   |   | (10,674 | ) |   |   | -32 | % |
| Royalty revenue  |   |                     | 15,704 |   |   |   | 14,664 |     |   |   | 1,040 |   |   |   | 7 | % |
| Service revenue  |   |                     | 3,616  |   |   |   | 3,412  |     |   |   | 204 |   |   |   | 6 | % |
| Other revenue    |   |                     | 3,852  |   |   |   | 2,999  |     |   |   | 853 |   |   |   | 28 | % |
|             |   | $                        | 59,774 |   |   | $      | 68,146 |     |   | $ | (8,372 | ) |   |   | -12 | % |

----

Table of Contents

----

Table of Contents

|                           |   | Six Months EndedJune 30, |   |   |   |   |   |     |   |
|--------------------------------|--------|--------------------------|--------|--------|--------|--------|--------|----------|--------|
|                           |   | 2012                     |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| Revenue                        |   | $                        | 37,226 |   |   | $      | 22,767 |     |   | $ | 14,459 |   |   |   | 64 | % |
| Gross profit                   |   | $                        | 26,706 |   |   | $      | 14,268 |     |   |   | 12,438 |   |   |   | 87 | % |
| Gross profit margin percentage |   |                     | 72     | %      |   |   | 63     | %        |   |   | 9 | % |   |   | N/A |   |
| Operating expenses             |   | $                        | 23,153 |   |   | $      | 17,405 |     |   |   | 5,748 |   |   |   | 33 | % |
| Income (loss) from operations  |   | $                        | 3,553  |   |   | $      | (3,137 | )        |   |   | 6,690 |   |   |   | 213 | % |

|             |   | Six Months EndedJune 30, |   |   |   |   |   |     |   |
|------------------|--------|--------------------------|--------|--------|--------|--------|--------|----------|--------|
|             |   | 2012                     |   |   | 2011   |   |   | Variance |   |   | Variance (%) |   |
| System sales     |   | $                        | 1,346  |   |   | $      | 2,981  |     |   | $ | (1,635 | ) |   |   | -55 | % |
| Consumable sales |   |                     | 138    |   |   |   | 161    |     |   |   | (23 | ) |   |   | -14 | % |
| Royalty revenue  |   |                     | 253    |   |   |   | 4      |     |   |   | 249 |   |   |   | 6225 | % |
| Assay revenue    |   |                     | 34,807 |   |   |   | 18,845 |     |   |   | 15,962 |   |   |   | 85 | % |
| Service revenue  |   |                     | 278    |   |   |   | 261    |     |   |   | 17 |   |   |   | 7 | % |
| Other revenue    |   |                     | 404    |   |   |   | 515    |     |   |   | (111 | ) |   |   | -22 | % |
|             |   | $                        | 37,226 |   |   | $      | 22,767 |     |   | $ | 14,459 |   |   |   | 64 | % |

----

Table of Contents

|                      |   | June 30, 2012  |    |   | December 31, 2011 |   |
|---------------------------|--------|----------------|---------|--------|-------------------|--------|
|                      |   | (in thousands) |    |
|                      |   |           |    |   |              |   |
| Cash and cash equivalents |   | $              | 75,898  |   |              | $      | 58,282 |   |
| Short-term investments    |   |           | 23,150  |   |              |   | 42,574 |   |
| Long-term investments     |   |           | 5,997   |   |              |   | 6,151 |   |
|                      |   | $              | 105,045 |   |              | $      | 107,007 |   |

----

Table of Contents

ITEM 3

----

Table of Contents

ITEM 4.

PART II

ITEM 1A

ITEM 2.

| ISSUER PURCHASES OF EQUITY SECURITIES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   | Total Number of Shares Purchased (1) |   |   | Average Price Paid per Share |   |   | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2) |   |   | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (2) |   |
| 04/01/12 - 04/30/12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   |   | 60,002 |   |   | $ | 24.86 |   |   |   | 59,800 |   |   | $ | 16,884,000 |   |
| 05/01/12 - 05/31/12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   |   | 71,969 |   |   |   | 22.29 |   |   |   | 65,627 |   |   |   | 14,587,055 |   |
| 06/01/12 - 06/30/12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   |   | 88,292 |   |   |   | 21.89 |   |   |   | 62,900 |   |   |   | 12,385,555 |   |
| Total Second Quarter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |   | 220,263 |   |   | $ | 22.83 |   |   |   | 188,327 |   |   | $ | 12,385,555 |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| (1) Total shares purchased includes shares attributable to the withholding of shares by Luminex to satisfy the payment of tax obligations related to the vesting of restricted shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| (2) These shares were purchased in open-market transactions pursuant to a share repurchase program publicly announced on November 17, 2010. On May 19, 2011, our original repurchase program was amended to increase the then remaining value of allowable shares to be purchased from $15.77 million to $18.75 million in aggregate purchase price through February 6, 2012. On February 2, 2012, the Board of Directors authorized the repurchase of common stock up to the lesser of $22.75 million, or 650,000 shares, of its outstanding common stock. This new stock repurchase program is scheduled to expire on December 31, 2012. The repurchase program does not obligate us to acquire any particular amount of common stock and the repurchase program may be suspended at any time at our discretion. |   |

----

Table of Contents

ITEM 6

| ExhibitNumber |   |  Description of Documents                                                                                                                                                                                                                                                                                                                                                          |
|---------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.1*         |   | Luminex Corporation Second Amended and Restated 2006 Equity Incentive Plan (Previously filed as Annex A to the Company’s Proxy Statement for its Annual Meeting of Stockholders held on May 17, 2012)                                                                                                                                                                             |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                    |
| 10.2*         |   | Luminex Corporation Employee Stock Purchase Plan (Previously filed as Annex B to the Company’s Proxy Statement for its Annual Meeting of Stockholders held on May 17, 2012)                                                                                                                                                                                                       |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                    |
| 31.1          |   | Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                    |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                    |
| 31.2          |   | Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                    |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                    |
| 32.1          |   | Certification by CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                    |
| 32.2          |   | Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                    |
| 101           |   | The following materials from Luminex Corporation’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012, formatted in XBRL: (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Statement of Cash Flows; and (iv) Notes to Condensed Consolidated Financial Statements. |

----

Table of Contents

SIGNATURES

----

Table of Contents

| ExhibitNumber |   |  Description of Documents                                                                                                                                                                                                                                                                                                                                                                |   |
|---------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|          |   |                                                                                                                                                                                                                                                                                                                                                                                          |   |
| 10.1*         |   | Luminex Corporation Second Amended and Restated 2006 Equity Incentive Plan (Previously filed as Annex A to the Company’s Proxy Statement for its Annual Meeting of Stockholders held on May 17, 2012)                                                                                                                                                                                   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.2*         |   | Luminex Corporation Employee Stock Purchase Plan (Previously filed as Annex B to the Company’s Proxy Statement for its Annual Meeting of Stockholders held on May 17, 2012)                                                                                                                                                                                                             |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                          |
| 31.1          |   | Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                          |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                          |
| 31.2          |   | Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                          |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                          |
| 32.1          |   | Certification by CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                      |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                          |
| 32.2          |   | Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                      |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                          |
| 101           |   | The following materials from Luminex Corporation’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012, formatted in XBRL: (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Statement of Cash Flows; and (iv) Notes to Condensed Consolidated Financial Statements.  |

----